Navigation Links
Misonix Previews New OsteoSculpt® Ultrasonic Bone Scalpel
Date:11/15/2010

FARMINGDALE, N.Y., Nov. 15, 2010 /PRNewswire/ -- Misonix, Inc. (Nasdaq: MSON), a developer of state of the art, ultrasonic medical device technology, which worldwide is used for acute health conditions, has announced its attendance and exhibition at the 20th Congress of the European Association for Cranial-Maxillofacial Surgery (EACMFS), which was held recently in Bruges, Belgium.  The EACMFS is widely regarded as the premier educational event for maxillofacial surgery in Europe.  Misonix used this venue to introduce its new OsteoSculpt® Ultrasonic Bone Scalpel for use in facial bone surgery.

During the meeting, Dr. Roland Gilles and his colleagues from Hospital CHC Liege in Belgium presented their initial experience with 28 patients in orthognatic surgery, exclusively using the OsteoSculpt for bone cutting.  The team described the OsteoSculpt as safe and beneficial for orthognatic and maxillofacial bone surgery with an absence of nerve lesions while reducing blood loss and operative time.  Their detailed findings will be published in the proceedings of the Congress late in the year.

The OsteoSculpt was developed with the help of Dr. Gilles and other surgeon innovators.  It is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures.  It offers the convenience and speed of a power instrument without the safety issues often associated with rotary or reciprocating sharps. Another Misonix product, the BoneScalpel™ has been successfully used in thousands of bone surgeries for spinal decompression, spinal fusion, and scoliosis on a worldwide basis at many prestigious academic institutions.

"Misonix is excited by the expanded surgical use of our ultrasonic bone cutting technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "The clinical benefits for patient and surgeon over traditional means of bone surgery are evident.  This is another example of our commitment to state-of-the-art medical devices for use by the worldwide medical community working in cooperation with visionary thought leaders."

About Misonix:Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment.  Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies.  Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications.  Additional information is available on the Company's Web site at www.misonix.com.

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995.  These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances.  Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.  The Company disclaims any obligation to update its forward-looking relationships.Investor Relations Contact:Kevin McGrath/Cameron Associates, Inc.212-245-4577Kevin@cameronassoc.com
'/>"/>

SOURCE Misonix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Misonix Reports First Quarter Fiscal 2011 Financial Results
2. Misonix Announces New Distribution Agreement for South Africa
3. Misonix Schedules First Quarter 2011 Financial Results Conference Call; November 15, 2010 at 4:30 P.M. Eastern
4. Misonix Announces Change in Distribution of SonaStar® Surgical Aspiration System in the U.S.
5. Misonix Reports Fourth Quarter and Fiscal Year 2010 Financial Results
6. Misonix Schedules Fourth Quarter and Fiscal 2010 Financial Results Conference Call; September 28, 2010 at 4:30 p.m. Eastern
7. Misonix Announces New Distribution Agreement For Spain
8. Misonix Announces New Distribution Agreement for France
9. Misonix Announces New Distribution Agreement for Russia
10. Misonix Announces New GPO Agreement With First Choice Cooperative
11. Misonix Announces New Distribution Agreement for Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, ... complete response letter from the U.S. Food and Drug ... approval of sirukumab for the treatment of moderately to ... indicates additional clinical data are needed to further evaluate ... to severely active RA. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... While it’s often important to take certain medications during ... Austin, Texas, has identified a solution. , She developed a prototype for MOTION LIGHT-UP ... such, it eliminates the need to turn on a light when taking medication during ...
(Date:10/13/2017)... ... 13, 2017 , ... Lori R. Somekh, founder of the Law Office ... of elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office ... forum to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
Breaking Medicine News(10 mins):